The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Update on the treatment of narcolepsy: clinical efficacy of pitolisant
|
|---|---|
| Published in |
Nature and science of sleep, April 2017
|
| DOI | 10.2147/nss.s103462 |
| Pubmed ID | |
| Authors |
Michael W Calik |
| Abstract |
Narcolepsy is a neurological disease that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness (EDS). In 60-70% of individuals with narcolepsy, it is also characterized by cataplexy or a sudden loss of muscle tone that is triggered by positive or negative emotions. Narcolepsy decreases the quality of life of the afflicted individuals. Currently used drugs treat EDS alone (modafinil/armodafinil, methylphenidate, and amphetamine), cataplexy alone ("off-label" use of antidepressants), or both EDS and cataplexy (sodium oxybate). These drugs have abuse, tolerability, and adherence issues. A greater diversity of drug options is needed to treat narcolepsy. The small molecule drug, pitolisant, acts as an inverse agonist/antagonist at the H3 receptor, thus increasing histaminergic tone in the wake promoting system of the brain. Pitolisant has been studied in animal models of narcolepsy and used in clinical trials as a treatment for narcolepsy. A comprehensive search of online databases (eg, Medline, PubMed, EMBASE, the Cochrane Library Database, Ovid MEDLINE, Europe PubMed Central, EBSCOhost CINAHL, ProQuest Research Library, Google Scholar, and ClinicalTrials.gov) was performed. Nonrandomized and randomized studies were included. This review focuses on the outcomes of four clinical trials of pitolisant to treat narcolepsy. These four trials show that pitolisant is an effective drug to treat EDS and cataplexy in narcolepsy. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 76 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 18% |
| Student > Bachelor | 10 | 13% |
| Researcher | 9 | 12% |
| Student > Ph. D. Student | 7 | 9% |
| Other | 6 | 8% |
| Other | 11 | 14% |
| Unknown | 19 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 17% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Neuroscience | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 11 | 14% |
| Unknown | 22 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2024.
All research outputs
#2,751,704
of 25,584,565 outputs
Outputs from Nature and science of sleep
#132
of 634 outputs
Outputs of similar age
#49,324
of 324,462 outputs
Outputs of similar age from Nature and science of sleep
#6
of 11 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 634 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.5. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,462 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.